## Supplemental information

Identifying biomarkers of differential

chemotherapy response in TNBC patient-derived

xenografts with a CTD/WGCNA approach

Varduhi Petrosyan, Lacey E. Dobrolecki, Lillian Thistlethwaite, Alaina N. Lewis, Christina Sallas, Ramakrishnan R. Srinivasan, Jonathan T. Lei, Vladimir Kovacevic, Predrag Obradovic, Matthew J. Ellis, C. Kent Osborne, Mothaffar F. Rimawi, Anne Pavlick, Maryam Nemati Shafaee, Heidi Dowst, Antrix Jain, Alexander B. Saltzman, Anna Malovannaya, Elisabetta Marangoni, Alana L. Welm, Bryan E. Welm, Shunqiang Li, Gerburg M. Wulf, Olmo Sonzogni, Chen Huang, Suhas Vasaikar, Susan G. Hilsenbeck, Bing Zhang, Aleksandar Milosavljevic, and Michael T. Lewis

Supplemental Figure 1 Related to Figures 1-3: Summary of all available PDX models. Furthest to the left is the treatment status for Carboplatin and Docetaxel. The middle set of bars is the biomarker status. The rightmost set of bars is the "omics" profiling status.

Supplemental Figure 2 Related to Figure 1: CNV Profiles of ER+ (Supplemental Figure 1A) PDXs and TCGA samples and HER2+ (Supplemental Figure 1B) PDX and TCGA samples.

Supplemental Figure 3 Related to Figure 2: Mutational profiles of ER+ (Supplemental Figure 2A) and HER2+ (Supplemental Figure 2B) PDXs and TCGA samples.